Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Lyme Disease Testing Market Poised To Hit $16.46 Billion By 2030 With A 9% CAGR

The lyme disease testing market has experienced robust expansion in recent years. Its valuation is projected to increase from $10.68 billion in 2025 to $11.67 billion in 2026, at a compound annual growth rate (CAGR) of 9.3%. This historical growth can be attributed to factors like a growing occurrence of lyme disease, insufficient understanding of early diagnosis, the continued use of conventional serological testing, an increase in hospital-based diagnostics, and expanding research into tick-borne illnesses.

The lyme disease testing market is projected to experience substantial expansion in the coming years, with its size anticipated to reach $16.46 billion in 2030, growing at a compound annual growth rate (CAGR) of 9.0%. This growth during the forecast period is attributable to the increasing adoption of AI-assisted diagnostics, a rise in home-testing kits, the expansion of multi-disease panels, enhanced government funding for tick-borne disease surveillance, and the integration of cloud-based laboratory data management. Significant trends expected during this period include the broader implementation of point-of-care testing, the development of home-based lyme disease diagnostics, the introduction of multi-pathogen tick-borne panels, increased adoption of rapid test kits, and the establishment of personalized diagnostic protocols.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=99755666&type=smp&name=Lyme%20Disease%20Testing%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Lyme Disease Testing Market Industry Drivers: What’s Behind The Revenue Growth?

An increase in tick-borne illnesses is anticipated to boost the expansion of the lyme disease testing market in the future. These illnesses encompass various diseases spread to humans via bites from infected ticks, which are tiny, blood-consuming parasites typically found in grassy, forested, or countryside environments. Growing demand for treatments for tick-borne conditions stems from the wider geographical distribution of ticks due to climate change, resulting in increased exposure and infection levels. Tick-borne illnesses drive the need for Lyme disease testing because they are the main way Lyme disease is transmitted, making early detection and diagnosis crucial for effectively handling the increasing number of infection cases. As an illustration, the U.S. Centers for Disease Control and Prevention (CDC), a federal public health agency based in the U.S., indicated in March 2025 that in 2023, more than 89,000 cases of Lyme disease were documented, signifying a persistent significant impact from tick-borne illnesses when compared to prior years. Consequently, the growing occurrence of tick-borne illnesses is stimulating the expansion of the lyme disease testing market.

Lyme Disease Testing Market Breakdown By Product Type And Application

The lyme disease testing market covered in this report is segmented –

1) By Test Type: Serological Tests, Nucleic Acid Tests, Urine Antigen Tests, Other Test Types

2) By Testing Methodology: Enzyme-Linked Immunosorbent Assay (ELISA), Weste Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), Other Emerging Technologies

3) By Disease Stage: Early Lyme Disease, Disseminated Lyme Disease, Chronic Lyme Disease, Asymptomatic Lyme Disease Detection

4) By Sample Type: Blood, Urine, Cerebrospinal Fluid(CSF), Other Blood Samples

5) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutions, Public Health Organizations

Subsegments:

1) By Serological Tests: Enzyme-Linked Immunosorbent Assay, Western Blot, Immunofluorescence Assay (IFA), Line Immunoassay (LIA)

2) By Nucleic Acid Tests: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Next-Generation Sequencing (NGS)

3) By Urine Antigen Tests: Lateral Flow Assay, Enzyme Immunoassay (EIA), Immunoblot Urine Tests

4) By Other Test Types: Culture-Based Tests, Tick-Borne Co-Infection Panels, Artificial Intelligence-Assisted Diagnostic Tools

#Lyme Disease Testing Market Growth Trends: What’s Shaping The Future Outlook?

Leading companies operating within the Lyme disease testing market are concentrating on technological advancements in diagnostic instruments to improve testing precision, shorten turnaround times, and facilitate the early-stage identification of the disease. Diagnostic tools encompass medical devices, kits, or technologies utilized to ascertain the presence of Lyme disease by detecting specific antibodies, antigens, or genetic material associated with the Borrelia burgdorferi bacteria. For instance, in August 2024, EpitogenX Ltd., a UK-based biotechnology firm, announced the launch of a cutting-edge Lyme Disease Diagnostic Kit. This is an ELISA-based assay developed using their proprietary EpitoGen platform. It integrates ~120 distinct Borrelia epitopes, providing high specificity and sensitivity, and is crafted for research use (RUO). The kit supports early, strain-specific detection and can be adapted for diverse laboratory applications. Intended for research and diagnostic laboratories, it is optimal for enhancing detection accuracy and allowing for deeper insights into Lyme disease.

Lyme Disease Testing Market Leading Companies And Competitive Benchmarking

Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., Seegene Inc.

View The Full Lyme Disease Testing Market Report:

https://thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Lyme Disease Testing Market Largest Region By Revenue And Market Share

North America was the largest region in the lyme disease testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model